Annex 2 provides “additional GCP considerations, focusing on trials that incorporate decentralised elements, pragmatic elements and/or real-world data (RWD)”. Although ICH-GCP’s focus is on clinical trials with medicinal products, the new guidance specifically the ones on RWD can be relevant for medical devices Post-Market Clinical Followup studies. These considerations include but are not limited to: Ethics […]
Lees meer